[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skeletal-muscle-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skeletal-muscle-injury":52},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100626585",false,"NCT07437547","BPC 157 for Acute Hamstring Muscle Strain Repair","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI","BPC-HAMSTR","Inclusion Criteria:\n\n* Age 18 to 45 years.\n* Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening.\n* MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion.\n* Pre-injury physical activity \\>= 3 sessions\u002Fweek or participation in organized recreational sport.\n* Willingness to follow the standardized rehabilitation protocol and attend all study visits.\n* For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose.\n\nExclusion Criteria:\n\n* Grade III hamstring tear, tendon avulsion, or injury requiring surgical management.\n* Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment.\n* Prior hamstring strain on the index limb within the past 6 months.\n* Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides\u002Fgrowth factors within 30 days prior to screening.\n* Known bleeding disorder or current therapeutic anticoagulation.\n* Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk.\n* Known allergy or hypersensitivity to components of the investigational product or placebo.\n* Pregnant or breastfeeding.\n* Current participation in another interventional clinical study or participation within 30 days prior to screening.\n* Currently subject to a formal anti-doping testing program (e.g., WADA\u002FUSADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority","ALL","18 Years","45 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.",[27,28],"Hamstring Muscle Strain","Skeletal Muscle Injury",[30,31,32,33,34,35,36,37,38,39],"BPC 157","BPC-157","pentadecapeptide","muscle strain","hamstring injury","sports medicine","MRI","return to play","muscle repair","rehabilitation","RECRUITING","2026-02-22",{"date":43,"type":44},"2026-02-27","ACTUAL",{"date":46,"type":44},"2026-02-02",{"date":48,"type":21},"2028-02-17",{"name":50,"class":51},"Hudson Biotech","INDUSTRY",""]